Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:06 PM ET 8-K
Reverse Stock Split Nextnrg, Inc. NXXT

Nextnrg Reverse Stock Split

NextNRG, Inc. implemented a 1-for-10 reverse stock split of its common stock effective September 14, 2026. The split reduced the number of outstanding shares from approximately 168.4 million to 16.8 million to adjust the per-share trading price on the Nasdaq Capital Market.

4:06 PM ET 8-K
Executive Compensation Vaxart, Inc. VXRT

Vaxart Executive Compensation

Vaxart's Board of Directors approved a new Director Stock Ownership Policy requiring non-employee directors to hold stock valued at two times their annual cash retainer. The Board also adopted a Director Resignation Policy requiring directors to tender their resignation if they receive more 'withhold' than 'for' votes in an uncontested election.

4:06 PM ET 8-K
Executive Compensation Lesaka Technologies Inc LSAK

Lesaka Technologies Executive Compensation

Lesaka Technologies increased the annual base salary for Group CFO Dan Smith to approximately $447,053 and established fiscal 2027 cash incentive award structures for four senior executives. The incentive awards for Messrs. Heilbron, Kola, Mali, and Smith are based on a mix of quantitative financial performance and qualitative objectives, with maximum potential payouts of 120% of their respective base salaries.

Term
Fiscal 2027
4:06 PM ET 8-K
Leadership Change Inseego Corp. INSG

Inseego Leadership Change

Stephen Bye resigned from the Board of Directors of Inseego Corp., effective September 30, 2026. His departure is due to his upcoming appointment as CEO of WW International, Inc. and is not the result of any disagreement with the company.

Counterparty
Stephen Bye
4:06 PM ET Form 4
Insider Buying Smith Douglas Homes Corp. SDHC

Smith Douglas Homes Insider Thomas L. Bradbury Buys $200K of Stock

Thomas L. Bradbury bought 19,360 shares of Smith Douglas Homes Corp. at $10.31 a share, worth $200K in total on Sep 10, 2026. Shares held after the trade: 78,278 (+32.9%).

Value
$200K
Shares
19,360
Price
$10.31
Holding change
+32.9%
Trade date
Sep 10, 2026
4:06 PM ET Form 4
Insider Selling Quicklogic Corp QUIK

Quicklogic Sr. VP and CTO Timothy Saxe Sells $164K of Stock

Timothy Saxe, Sr. VP and CTO, sold 15,190 shares of Quicklogic Corp at $10.80 a share, worth $164K in total on Sep 10, 2026. Shares held after the trade: 143,976 (-9.5%).

Value
$164K
Shares
15,190
Price
$10.80
Role
Sr. VP and CTO
Holding change
-9.5%
Trade date
Sep 10, 2026
4:06 PM ET Form 4
Insider Selling Teladoc Health, Inc. TDOC

Teladoc Health CEO Charles Divita III Sells $109K of Stock

Charles Divita III, CEO, sold 17,805 shares of Teladoc Health, Inc. at $6.10 a share, worth $109K in total on Sep 11, 2026. Shares held after the trade: 465,535 (-3.7%).

Value
$109K
Shares
17,805
Price
$6.10
Role
CEO
Holding change
-3.7%
Trade date
Sep 11, 2026
4:06 PM ET Form 4
Insider Selling Nasdaq, Inc. NDAQ

Nasdaq EVP, CSO Jeremy Skule Sells $106K of Stock

Jeremy Skule, EVP, CSO, sold 1,125 shares of Nasdaq, Inc. at $94.22 a share, worth $106K in total on Sep 10, 2026. Shares held after the trade: 101,198 (-1.1%).

Value
$106K
Shares
1,125
Price
$94.22
Role
EVP, CSO
Holding change
-1.1%
Trade date
Sep 10, 2026
4:06 PM ET 8-K
Financial Results Kestra Medical Technologies, Ltd. KMTS

Kestra Medical Technologies Financial Results

Kestra Medical Technologies reported first quarter fiscal 2027 revenue of $31.0 million, a 60% increase year-over-year, driven by wearable cardioverter defibrillator (WCD) market expansion and competitive gains. The company reported a GAAP net loss of $44.1 million and increased its full-year fiscal 2027 revenue guidance to $141 million.

Term
Q1 2027
Earnings call
Sep 14, 2026, 4:30 PM ET

“Kestra delivered another strong quarter of financial performance, generating revenue growth of 60% while expanding gross margin to over 56%. We remain confident that our focus on innovation and commercial expansion positions Kestra to generate durable, top-tier growth for years to come. Our team is executing on its commitments to prescribers and their patients and we believe this will continue to drive market expansion and advance Kestra on its path to market leadership.”

Brian Webster, President and CEO
4:05 PM ET Form 4
Insider Selling Quicklogic Corp QUIK

Quicklogic President and CEO Brian C. Faith Sells $273K of Stock

Brian C. Faith, President and CEO, sold 25,292 shares of Quicklogic Corp at $10.80 a share, worth $273K in total on Sep 10, 2026. Shares held after the trade: 255,791 (-9.0%).

Value
$273K
Shares
25,292
Price
$10.80
Role
President and CEO
Holding change
-9.0%
Trade date
Sep 10, 2026
4:05 PM ET Form 4
Insider Buying American Homes 4 Rent AMH

American Homes 4 Rent Insider Jack E. Corrigan Buys $194K of Stock

Jack E. Corrigan bought 9,000 shares of American Homes 4 Rent at $21.47 to $21.60 a share (average $21.51) in 4 transactions, worth $194K in total between Sep 10, 2026 and Sep 11, 2026. Shares held after the trade: 25,000 (+19.0%).

Value
$194K
Shares
9,000
Average price
$21.51
Holding change
+19.0%
Trade date
Sep 10, 2026 to Sep 11, 2026
4:05 PM ET 8-K
M&A Deal CPI Card Group Inc. PMTS

CPI Card Group M&A Deal with Tricor Pacific Capital Partners

CPI Card Group Inc. announced the closing of a secondary public offering of 2,687,921 shares of common stock by selling stockholders Tricor Pacific Capital Partners. The offering included the full exercise of the underwriters' option to purchase additional shares, and the company received zero proceeds from the sale as it was entirely a resale of shares by existing holders.

Counterparty
Tricor Pacific Capital Partners (Fund IV)
4:05 PM ET Form 4
Insider Selling Quicklogic Corp QUIK

Quicklogic CFO, SVP Finance Elias Nader Sells $131K of Stock

Elias Nader, CFO, SVP Finance, sold 12,152 shares of Quicklogic Corp at $10.80 a share, worth $131K in total on Sep 10, 2026. Shares held after the trade: 82,255 (-12.9%).

Value
$131K
Shares
12,152
Price
$10.80
Role
CFO, SVP Finance
Holding change
-12.9%
Trade date
Sep 10, 2026
4:04 PM ET 8-K
Shareholder Meeting Elicio Therapeutics, Inc. ELTX

Elicio Therapeutics Shareholder Meeting

Elicio Therapeutics has scheduled its 2026 Annual Meeting of Stockholders for November 12, 2026. Because the meeting date has shifted by more than 30 days from the prior year's anniversary, the company established September 24, 2026, as the new deadline for shareholder proposals and director nominations.

4:03 PM ET Form 4
Insider Selling Dexcom Inc DXCM

Dexcom EVP, Chief Financal Officer Jereme M. Sylvain Sells $303K of Stock

Jereme M. Sylvain, EVP, Chief Financal Officer, sold 3,638 shares of Dexcom Inc at $83.27 a share, worth $303K in total on Sep 10, 2026. Shares held after the trade: 146,828 (-2.4%).

Value
$303K
Shares
3,638
Price
$83.27
Role
EVP, Chief Financal Officer
Holding change
-2.4%
Trade date
Sep 10, 2026
4:03 PM ET 8-K
Investor Presentation Emergent BioSolutions Inc. EBS

Emergent BioSolutions Investor Presentation

Emergent BioSolutions CEO Joseph C. Papa is presenting at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company filed a formal investor presentation deck as an exhibit, which outlines its strategy for combating public health threats and provides updates on its medical countermeasure portfolio, including CYFENDUS and NARCAN.

Counterparty
H.C. Wainwright
4:02 PM ET Form 4
Insider Selling Hershey Co HSY

Hershey Insider Hershey Trust Co Trustee in Trust for Milton Hershey School Sells $3.47M of Stock

Hershey Trust Co Trustee in Trust for Milton Hershey School sold 19,963 shares of Hershey Co at $173.44 to $175.50 a share (average $173.87) in 6 transactions, worth $3.47M in total between Sep 10, 2026 and Sep 11, 2026. Shares held after the trade: 816,119 (-0.0%).

Value
$3.47M
Shares
19,963
Average price
$173.87
Holding change
-0.0%
Trade date
Sep 10, 2026 to Sep 11, 2026
4:02 PM ET Form 4
Insider Selling SOPHiA Genetics SA SOPH

SOPHiA Genetics Executive Chairman Jurgi Camblong Sells $65.1K of Stock

Jurgi Camblong, Executive Chairman, sold 8,500 shares of SOPHiA Genetics SA at $7.66 a share, worth $65.1K in total on Sep 10, 2026. Shares held after the trade: 3,435,822 (-0.2%).

Value
$65.1K
Shares
8,500
Price
$7.66
Role
Executive Chairman
Holding change
-0.2%
Trade date
Sep 10, 2026
4:02 PM ET Form 4
Insider Selling SOPHiA Genetics SA SOPH

SOPHiA Genetics CLO Well Daan Van Sells $47.1K of Stock

Well Daan Van, CLO, sold 6,168 shares of SOPHiA Genetics SA at $7.63 a share, worth $47.1K in total on Sep 11, 2026. Shares held after the trade: 338,884 (-1.8%).

Value
$47.1K
Shares
6,168
Price
$7.63
Role
CLO
Holding change
-1.8%
Trade date
Sep 11, 2026
4:02 PM ET Form 4
Insider Selling Semtech Corp SMTC

Semtech EVP and CFO Mark Lin Sells $109K of Stock

Mark Lin, EVP and CFO, sold 683 shares of Semtech Corp at $159.90 a share, worth $109K in total on Sep 10, 2026. Shares held after the trade: 35,366 (-1.9%).

Value
$109K
Shares
683
Price
$159.90
Role
EVP and CFO
Holding change
-1.9%
Trade date
Sep 10, 2026
4:02 PM ET 8-K
Capital Raise Yarrow Bioscience, Inc. YARW

Yarrow Bioscience Capital Raise of $172M

Yarrow Bioscience entered into an underwriting agreement to sell 5,769,231 shares of common stock at $26.00 per share. The underwriters fully exercised their option to purchase an additional 865,384 shares, bringing the total expected net proceeds to approximately $161.8 million after expenses.

Value
$172M
Counterparty
Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC
4:01 PM ET Form 4
Insider Selling Kanzhun Ltd BZ

Kanzhun CEO Peng Jonathan Zhao Sells $6.12M of Stock

Peng Jonathan Zhao, CEO, sold 743,600 shares of Kanzhun Ltd at $8.18 to $8.28 a share (average $8.23) in 2 transactions, worth $6.12M in total between Sep 10, 2026 and Sep 11, 2026. Shares held after the trade: 2,824,080 (-11.3%).

Value
$6.12M
Shares
743,600
Average price
$8.23
Role
CEO
Holding change
-11.3%
Trade date
Sep 10, 2026 to Sep 11, 2026
4:01 PM ET 8-K
Investor Presentation Niki BioSolutions, Inc. NIKI

Niki BioSolutions Investor Presentation

Niki BioSolutions filed its corporate PowerPoint presentation which was presented by President & COO Alidad Mireskandari at the H.C. Wainwright Global Investment Conference in September 2026. The presentation highlights the company's recent all-stock merger with DiamiR Biosciences, which was completed on July 20, 2026.

Counterparty
H.C. Wainwright Global Investment Conference
4:01 PM ET 8-K
Investor Presentation Kairos Pharma, LTD. KAPA

Kairos Pharma Investor Presentation

Kairos Pharma, Ltd. issued a new investor presentation to be presented by CEO John Yu at the H.C. Wainwright 28th Annual Global Investment Conference in New York. The presentation provides an update on the company's clinical programs and activities.

Counterparty
H.C. Wainwright 28th Annual Global Investment Conference
4:01 PM ET Form 4
Insider Selling Amylyx Pharmaceuticals, Inc. AMLX

Amylyx Pharmaceuticals CFO James M. Frates Sells $350K of Stock

James M. Frates, CFO, sold 10,810 shares of Amylyx Pharmaceuticals, Inc. at $32.27 to $33.23 a share (average $32.36) in 2 transactions, worth $350K in total on Sep 10, 2026. Shares held after the trade: 233,625 (-0.4%).

Value
$350K
Shares
10,810
Average price
$32.36
Role
CFO
Holding change
-0.4%
Trade date
Sep 10, 2026
4:01 PM ET Form 4
Insider Selling Amylyx Pharmaceuticals, Inc. AMLX

Amylyx Pharmaceuticals CMO Camille L. Bedrosian Sells $325K of Stock

Camille L. Bedrosian, CMO, sold 10,028 shares of Amylyx Pharmaceuticals, Inc. at $32.21 to $33.09 a share (average $32.40) in 2 transactions, worth $325K in total on Sep 10, 2026. Shares held after the trade: 278,064 (-0.7%).

Value
$325K
Shares
10,028
Average price
$32.40
Role
CMO
Holding change
-0.7%
Trade date
Sep 10, 2026
4:01 PM ET Form 4
Insider Buying Ecovyst Inc. ECVT

Ecovyst Insider Patti A. Humble Buys $250K of Stock

Patti A. Humble bought 24,875 shares of Ecovyst Inc. at $10.05 a share, worth $250K in total on Sep 10, 2026. Shares held after the trade: 33,974 (+273.4%).

Value
$250K
Shares
24,875
Price
$10.05
Holding change
+273.4%
Trade date
Sep 10, 2026
4:01 PM ET 8-K
Clinical Trial Data Moleculin Biotech, Inc. MBRX

Moleculin Biotech Clinical Trial Data

Moleculin Biotech announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific venues in September 2026, including the AACR Conference on Pancreatic Cancer. The presentations will cover the drug's organotropism, its mechanism for targeting topoisomerase II, and its ability to stimulate CD8+ T cell cytotoxicity in pancreatic tumors. These findings support the company's broader development of Annamycin beyond its lead indication in acute myeloid leukemia (AML).

Counterparty
American Association for Cancer Research (AACR)
4:00 PM ET Form 4
Insider Selling Amylyx Pharmaceuticals, Inc. AMLX

Amylyx Pharmaceuticals Co-CEO Justin B. Klee Sells $980K of Stock

Justin B. Klee, Co-CEO, sold 30,464 shares of Amylyx Pharmaceuticals, Inc. at $32.13 to $33.16 a share (average $32.18) in 2 transactions, worth $980K in total on Sep 10, 2026. Shares held after the trade: 3,613,056 (-0.0%).

Value
$980K
Shares
30,464
Average price
$32.18
Role
Co-CEO
Holding change
-0.0%
Trade date
Sep 10, 2026
4:00 PM ET Form 4
Insider Selling Amylyx Pharmaceuticals, Inc. AMLX

Amylyx Pharmaceuticals Co-CEO Joshua B. Cohen Sells $981K of Stock

Joshua B. Cohen, Co-CEO, sold 30,464 shares of Amylyx Pharmaceuticals, Inc. at $32.16 to $33.15 a share (average $32.19) in 2 transactions, worth $981K in total on Sep 10, 2026. Shares held after the trade: 3,613,123 (-0.0%).

Value
$981K
Shares
30,464
Average price
$32.19
Role
Co-CEO
Holding change
-0.0%
Trade date
Sep 10, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.